# Study to Evaluate the Efficacy and Safety of CKD-350

> **NCT02777723** · PHASE3 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 138 (estimated)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** Xenobella
- **DRUG:** Isotonic 0.3% Sodium Hyaluronate

## Key facts

- **NCT ID:** NCT02777723
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2016-07
- **Final completion:** 2016-09
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02777723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02777723, "Study to Evaluate the Efficacy and Safety of CKD-350". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02777723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*